Leaflet MELLEVA 35 2mg / 0.035mg film-coated tablets
Indicated for: androgen-dependent acne; hirsutism; contraception
Route of administration: oral
Substance: cyproterone + ethinylestradiol (antiandrogen + estrogen)
ATC: G03HB01 (Genito urinary system and sex hormones | Antiandrogens | Antiandrogens and estrogens)
Use during breastfeeding only on medical advice.
The combination of cyproterone and ethinylestradiol is used for the treatment of severe acne, hirsutism, and other conditions caused by excess androgens in women. Cyproterone is an antiandrogen that reduces the effects of androgen hormones, while ethinylestradiol is an estrogen that regulates the menstrual cycle.
The medication is taken orally, as directed by a doctor, usually once daily at the same time each day. It is important for patients to follow the treatment regimen to achieve maximum benefits.
Patients should be aware of potential side effects, such as nausea, headaches, or mood changes. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, headaches, and breast tenderness. In rare cases, severe reactions such as venous thromboembolism or allergic reactions may occur. Patients should be informed of these risks before starting treatment.
General data about MELLEVA 35 2mg / 0.035mg
- Substance: cyproterone + ethinylestradiol
- Date of last drug list: 01-01-2014
- Commercial code: W52427001
- Concentration: 2mg / 0.035mg
- Pharmaceutical form: film-coated tablets
- Quantity: 1
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).